Wave Life Sciences (WVE) Q3 FY26 earnings call

A pipeline-execution quarter with no efficacy readouts: the story is regulatory de-risking of the RNA-editing asset and ramp of the obesity program into target populations. Value inflection depends on Q4 data (WVE-006 600 mg, WVE-007 600 mg SAD) and possible early Phase IIa body-composition data, while management keeps key bars undisclosed on competitive grounds.